S1PR4 and metabolic dysfunction-associated steatohepatitis: Furthermore, it has also been reported that sphingosine 1 phosphate receptor 4 (S1PR4) may be a new therapeutic target for NASH, mediating the activation of NLRP3 inflammasome in hepatic macrophages through inositol trisphosphate/inositol trisphosphate-receptor-dependent [Ca2+] signaling [125].